Skip Navigation

Oncology

Investigation of Low-dose Abdominal Radiation Therapy for the Treatment of Feline Small Cell Gastrointestinal Lymphoma

TitleInvestigation of Low-dose Abdominal Radiation Therapy for the Treatment of Feline Small Cell Gastrointestinal Lymphoma
Contact Person Please contact Carrissa Wood, DVM directly with any questions regarding this trial and how to refer patients for consideration.
cwood@cvm.tamu.edu or 979-845-2351, Email is preferred route of contact to ensure the quickest turnaround.
Species Feline
Inclusion Criteria and General Background Information
  • Are greater than 1 year of age
  • Are any breed, size, sex, and weigh at least 2 Kg (4.5 lbs)
  • Confirmed histopathologic diagnosis of small cell gastrointestinal lymphoma.
  • No other series co-morbidities or other neoplasia (advanced heart disease, advanced kidney disease, etc)
  • Have no evidence of spread of the tumor outside the intestines, liver, spleen or lymph nodes within the abdomen at enrollment
  • Be deemed a good anesthetic candidate for 2 anesthesia periods, 24 hours apart
  • Must be on chlorambucil chemotherapy for > 1 month < 6 months prior to radiation therapy
  • Must be deemed during staging to be in a complete or partial remission based on intestinal infiltration.

The purpose of this clinical trial is to determine if the addition of radiation therapy to the intestines is effective at delaying the recurrence of lymphoma within the intestines when used in addition to the standard of care treatment chemotherapy.

The study will include a pre-radiation work up (CBC, Chemistry, urinalysis, three view thoracic radiographs, and abdominal ultrasound), one CT scan for radiation therapy planning (done prior to and under the same anesthesia as the administration of the first radiation dose) and two episodes of radiation under generalized anesthesia administered 24 hours apart. Follow up rechecks at Texas A&M Small Animal Teaching Hospital at 2 weeks, 1 month, and every 3 months after completion of radiation therapy until relapse of disease or discontinued by investigators.
Exclusion Criteria
Owner Commitments The owner of any participating animal is financially responsible for costs associated with the treatment of complications or accidental injuries associated with this study. Should the study patient experience an unanticipated side effect directly associated (as determined by a review committee of oncologist at TAMU) with radiation therapy, a stipend of up to $1000 dollars for treatment management will be provided.
Financial Incentives

The owner is responsible for pre-enrollment diagnostics to meet eligibility criteria (including but not limited to a complete blood count, chemistry panel, urinalysis, chest x-rays and aspirate or biopsy of the tumor), abdominal ultrasound, and the cost of standard of care chemotherapy. Should the patient be found eligible the owner will be reimbursed:

  • the cost of the pre-radiation therapy CBC, chemistry, urinalysis chest radiographs and abdominal ultrasound costs
  • the cost of radiation therapy (including anesthesia and associated hospitalization charges) will be covered by the study.
  • the subsequent follow up recheck exams after completion of radiation therapy until relapse of disease or discontinued by investigators will be covered up to $250 per visit.

AKC-CHF PET 2.0 T-cell therapy in dogs with B-cell lymphoma

TitleAKC-CHF PET 2.0 T-cell therapy in dogs with B-cell lymphoma
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information

Must be a canine patient diagnosed with B-cell lymphoma, weigh at least 10 kg, and is in good general health (outside of lymphoma diagnosis). Must be Stage 4 or less, substagea.

 

AKC-CHF PET 2.0 is a T-cell therapy using CAVU Biotherapies patent-pending techniques. In this study, autologous, activate, and non-specific T cells are generated using a peripheral blood sample from a companion canine who has been diagnosed with Stage IV B-cell lymphoma. Because the newly generate T-cells are not genetically modified, they should respond similarly to all immuno-suppressive regimens and should have a similar safety and toxicity outcomes as an earlier 2012 study. Enrolled patients are set to receive, 2 cycles of CHOP (8 weeks each cycle), a single high-dose of Cytoxan, and followed with two t-cell infusions.

Exclusion Criteria

Canine individuals will not be eligible if they have ever received any form of other chemotherapy, received investigational therapy or radiation therapy. Canine patient must not have been given steroids for at least 7 days prior to enrollment.

Owner Commitments

Staging expenses will be paid for by the owner (with the exception of the lymph node measurements, cytology and immunophenotyping). The staging test will be determined by the senior clinician. In addition, any costs associated with the treatment of complications or accidental injuries associated with this study will also be covered at the owner's expense. After T-cell therapy is complete, follow-up with the patient will be required up until tumor recurrence. Patients are not required to travel to TAMU for continued monitoring.

Financial Incentives

Enrolled canine patients are eligible to receive up to $1,500, per patient. This will be used to pay for the chemotherapy (2 cycles of CHOP), a single high-dose of cytoxan, and two T-cell infusions.

Whole Lung Irradiation for the Treatment of Osteosarcoma in Dogs

TitleWhole Lung Irradiation for the Treatment of Osteosarcoma in Dogs
Contact Person Heather Wilson, DVM, DACVIM (Oncology)
Hospital Phone: 979-845-2351
Email: oncology@cvm.tamu.edu
Species Canines
Inclusion Criteria and General Background Information

Dogs are eligible if they:

  • Have been diagnosed with osteosarcoma (or suspected osteosarcoma) of a limb that is amenable to surgery
  • Are > 1 year of age.
  • Weigh > 15 kg (33 lbs).
  • Do not have significant blood work abnormalities.
  • Have not had any previous therapy for osteosarcoma.
  • Have not had previous cancer therapy for any tumor within 2 weeks of enrollment.
  • Are ambulatory and capable of eating and going outside without assistance.

The purpose of this clinical trial is to evaluate the efficacy of radiation therapy targeted towards the lungs following standard of care treatment for dogs with osteosarcoma. Whole lung irradiation has been shown to delay the time to development of metastasis in people with osteosarcoma. The efficacy of this treatment has not been investigated in dogs.

Exclusion Criteria

Dogs will be excluded from the study if they:

  • Have no measurable disease (tumor) at enrollment.
  • Have evidence of regional or distant metastatic disease at the time of diagnosis.
  • Have any other serious medical condition (hepatic, cardiovascular, endocrine, etc)
  • Have a known sensitivity to carboplatin.
  • Are pregnant or likely to become pregnant.
Owner Commitments
  • Owners are responsible for the cost of initial diagnostics and staging tests required for enrollment (estimated to cost $800-$1200).
  • Owners must be willing to complete standard of care treatment for osteosarcoma. This includes amputation of the affected (diseased) limb and 4 treatments of carboplatin chemotherapy.
  • Owners must be willing to complete all treatments at TAMU including 10 daily treatments of radiation to the lungs administered over 2 weeks (animals can be boarded during this time).
  • Owners must be willing to return to TAMU for rechecks every 2 months after treatments are completed for up to 12 months.
Financial Incentives
  • Surgical limb amputation at TAMU
    • Study will pay $1000 towards amputation
  • Carboplatin treatments (x 4)
    • Study will pay $150 towards each carboplatin treatment
  • Whole lung irradiation including CT-sim and diagnostics scheduled throughout treatment
    • Entirely paid for by study
  • Recheck and chest x-rays every 8 weeks thereafter
    • Entirely paid for by study